Gilead Sciences (GILD) Tops Q1 EPS by 4c; maintains guidance

Gilead Sciences (NASDAQ: GILD) reported Q1 EPS of $1.81, $0.04 better than the analyst estimate of $1.77. Revenue for the quarter came in at $6.67 billion versus the consensus estimate of $6.78 billion.

GUIDANCE:

Gilead Sciences sees FY2025 EPS of $7.70-$8.10, versus the consensus of $7.95. Gilead Sciences sees FY2025 revenue of $28.2-28.6 billion, versus the consensus of $28.729 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

You May Also Be Interested In

• S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
• lululemon athletica (LULU) Tops Q2 EPS by $1.10, Cuts Guidance
• S&P announces major changes in S&P 100, S&P 500, S&P 400